The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCC

Brian Rini, MD
Published Online:4:17 PM, Thu July 13, 2017

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses the basis for the ongoing phase III KEYNOTE-426 trial, which is exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) versus sunitinib (Sutent) alone in treatment-naive advanced metastatic renal cell carcinoma.
 
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.